We reduce our earnings forecasts given the severity of the COVID-19 restrictions in New Zealand (NZ) and the heightened uncertainty in Australia. The virus crisis has deferred the anticipated recovery in SRG’s performance, but not cancelled it. We expect the balance sheet to handle the short-term strain on earnings and cash flow and maintain a BUY call on a revised valuation of $0.44 (prior $0.50).
To access the full report please log in under the Client Area at the bottom of this page.
Argonaut’s Client Area allows you to view delayed share prices, access Argonaut’s wealth of Research as well as create custom portfolios and set up company watch lists.
If you would like to access our research please contact us to create an account.